Heron Therapeutics Inc HRTX:NASDAQ

Last Price$19.29NASDAQ Previous Close - Last Trade as of 4:15PM ET 6/05/20

Today's Change+0.86(4.67%)
Bid (Size)$19.16 (23)
Ask (Size)$19.75 (1)
Day Low / High$18.56 - 19.51
Volume882.3 K

View Biotechnology IndustryPeer Comparison as of 06/05/2020


Heron Therapeutics Inc ( NASDAQ )

Price: $19.29
Change: +0.86 (4.67%)
Volume: 882.3 K
4:15PM ET 6/05/2020

Epizyme Inc ( NASDAQ )

Price: $17.18
Change: +0.07 (0.41%)
Volume: 770.4 K
4:15PM ET 6/05/2020

Xencor Inc ( NASDAQ )

Price: $30.01
Change: +0.14 (0.49%)
Volume: 412.0 K
4:15PM ET 6/05/2020

Akebia Therapeutics Inc ( NASDAQ )

Price: $11.96
Change: -0.22 (1.85%)
Volume: 1.2 M
4:15PM ET 6/05/2020

Adverum Biotechnologies Inc ( NASDAQ )

Price: $22.67
Change: +2.39 (11.82%)
Volume: 1.2 M
3:59PM ET 6/05/2020

Read more news Recent News

Analyst Actions: Guggenheim Starts Heron Therapeutics at Buy With $24 Price Target
9:28AM ET 5/27/2020 MT Newswires

Heron Therapeutics (HRTX) has an average analyst rating of buy, with an average price target of $42. Price: 19.05, Change: +0.61, Percent Change: +3.31 ...

Heron Therapeutics Commences Clinical Trial of Post-Operative Pain Medication
9:32AM ET 5/18/2020 MT Newswires

Heron Therapeutics (HRTX) said Monday that it has begun a phase 1b/2 clinical trial of HTX-034, the company's next-generation product for the treatment of...

Heron Therapeutics Q1 Loss Narrows, Revenue Declines
12:18PM ET 5/06/2020 MT Newswires

Heron Therapeutics (HRTX) on Wednesday posted a Q1 loss of $0.57, narrowing from $0.80 loss a year ago. Analysts polled by Capital IQ had expected a loss...

Heron Therapeutics Slips After Posting Worse-Than-Expected Q4 Loss Per Share; Revenue Tops Consensus
2:28PM ET 3/02/2020 MT Newswires

Heron Therapeutics (HRTX) on Monday posted a Q4 net loss of $0.65 per share, compared with a net loss of $0.63 per share a year earlier and wider than the...

Company Profile

Business DescriptionHeron Therapeutics, Inc. is a biotechnology company, which engages in the development of pharmaceutical products for patients suffering from cancer. Its products portfolio include SUSTOL, Cinvanti, HTX-011, and HTX-034. The company was founded in February 1983 and is headquartered in Redwood City, CA. View company web site for more details
Address4242 Campus Point Court
San Diego, California 92121
Number of Employees198
Recent SEC Filing06/04/20208-K
President, Chief Executive Officer & DirectorBarry D. Quart
Chief Financial Officer & Senior VP-FinanceRobert E. Hoffman
Chief Scientific Officer & SVP-PharmaceuticalThomas B. Ottoboni
Chief Medical OfficerChris M. Storgard

Company Highlights

Price Open$19.00
Previous Close$18.43
52 Week Range$9.60 - 26.81
Market Capitalization$1.7 B
Shares Outstanding90.6 M
SectorHealth Technology
Next Earnings Announcement08/03/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.27
Beta vs. S&P 500N/A
Revenue$77.5 M
Net Profit Margin-138.31%
Return on Equity-56.85%

Analyst Ratings as of 05/22/2020

Consensus RecommendationConsensus Icon
Powered by Factset